Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
June 28, 2016 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
June 16, 2016 16:05 ET
|
Paratek Pharmaceuticals
Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK)...
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
June 10, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 10, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
May 25, 2016 16:30 ET
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...
Cempra to Present Solithromycin IV Data at ATS 2016
May 12, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections
May 12, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, May 12, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results...
Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets
May 10, 2016 16:01 ET
|
Paratek Pharmaceuticals
FDA Affirms Chosen Comparator, Primary Endpoint for Phase 3 StudyStudy, if Conducted, Would Initiate Following the Reporting of Top-Line Data from IV-to-Oral ABSSSI Phase 3 StudyPotential to...
Cempra to Report First Quarter 2016 Financial Results
April 25, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9
March 08, 2016 16:10 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics to Present at BioCentury Future Leaders Conference
March 03, 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will present a clinical and...